Key facts
- BioAscent’s last known valuation is $4.3M (Jun 2018).
- It has raised $2.1M; the latest was Later Stage VC in Apr 2025.
- Notable investors include Maven Capital Partners UK, Pioneer Group.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for BioAscent
- ·The full record, as it builds
Funding rounds
No funding rounds for BioAscent are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BioAscent
Provider of integrated drug discovery services intended to reach key stages of the drug discovery process. The company offers a range of services, including target analysis, bespoke screening strategies, compound screening, and data management, enabling pharmaceutical businesses to maximize their lead findings and increase the success rate of discovery projects at a lower cost.
- Sector
- Healthcare
- HQ
- Motherwell, United Kingdom
- Founded
- 2013
- Employees
- 77
- Website
- bioascent.com/
- Ownership
- Privately Held (backing)
BioAscent doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioAscent shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioAscent in its N-PORT filings yet. We sweep new filings monthly.